Many scientists have been working on the application of Hsp90 inhibitors in cancer treatment, from first-generation drugs (Geldanamycin (GA) and Radicicol (RD)) [48] to second-generation drugs (related derivatives of GA and RD) [49]. Here, HSP90AA1 is linked to cancer.